Current Headlines

  1. Novel Specialized Film For Drug Development 3/5/2026

    A method developed at the Karlsruhe Institute of Technology (KIT) could make drug testing more reliable, accelerate drug development, and replace animal testing. The basis consists of three-dimensional cell culture systems that reflect the conditions in the human body better than cultures grown in Petri dishes.

  2. Frontage Laboratories Completes Acquisition Of Teddy Lab, Strengthening Global Central Laboratory Capabilities 3/4/2026

    rontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, today announced the completion of the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd. ("Teddy Lab"), a leading clinical research laboratory service provider in China.

  3. iLoF And Industry Leader Bluepharma Announce Strategic Collaboration To Deploy AI-Powered Optomics® For Faster Drug Development And To Advance The Future Of Personalised Medicine 3/4/2026

    iLoF, the leading company pioneering Optomics®, the AI-powered photonics platform for developing personalised solutions for drug development and clinical research, announces today a strategic collaboration with Bluepharma, a global pharmaceutical company specializing in the research, development, and manufacturing of innovative healthcare products.

  4. Ensorcell Appoints Biopharma Industry Veterans Geoff Hodge And Amy Teachout To Senior Leadership Team 3/3/2026

    Ensorcell, a company focused on reimaging life science tools and solutions for the biopharmaceutical industry, today announced the appointment of Geoff Hodge and Amy Teachout to its senior leadership team. These appointments reinforce Ensorcell’s commitment to innovation, superb value, and exceptional customer experience as the company continues to expand its capabilities and partnerships across the biopharma ecosystem.

  5. BioDuro And Cenra Launch Joint Venture To Expand Resilient Global API Manufacturing Capacity 3/3/2026

    BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech Co., Ltd. (CCSB), a leading pharmaceutical chemical manufacturer in Taiwan since 1964, to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra's campus in Taipei, Taiwan, to BioDuro's global network.

  6. Chemically 'Stapled' Peptides Used To Target Difficult-To-Treat Cancers 3/3/2026

    Researchers at the University of Bath have developed a new technology that uses bacteria to build, chemically stabilise, and test millions of potential drug molecules inside living cells, making it much quicker and easier to discover new treatments for difficult-to-treat cancers.

  7. Priovant Announces FDA Acceptance And Priority Review Of New Drug Application For Brepocitinib In Dermatomyositis 3/3/2026

    Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review.

  8. Insilico Medicine And Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models For Drug Discovery 3/3/2026

    Insilico Medicine and Liquid AI today announced a partnership that creates lightweight scientific foundation models for pharmaceutical research. The collaboration has produced LFM2-2.6B-MMAI (v0.2.1), available now – a single checkpoint trained to perform at state-of-the-art levels across multiple drug discovery subdomains, not a patchwork of separate point models.

  9. Gyre Therapeutics Enters Into Agreement To Acquire Cullgen To Gain Targeted Protein Degradation Platform And Pipeline 3/2/2026

    Gyre Therapeutics, Inc. (Gyre or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced its agreement to acquire Cullgen Inc. (Cullgen), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies, in an all-stock transaction valued at approximately $300 million.

  10. Sanofi's Rilzabrutinib Earns Orphan Drug Designation In Japan For IgG4-Related Disease 3/2/2026

    The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD).